RecruitingMultifocal Motor Neuropathy
A Clinical Study to Evaluate DNTH103 in Adults With Multifocal Motor Neuropathy
Eligible age
18–75 yrs
Accepts
All genders
Locations
7 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The purpose of this Phase 2 study is to evaluate the safety, tolerability, pharmacometrics, and efficacy of Claseprubart (DNTH103) in participants with multifocal motor neuropathy (MMN).
Sponsor: Dianthus Therapeutics
You may qualify if…
- ✓ 1. Must have given written informed consent before any study-related activities are carried out
- ✓ 2. Adult males and females, 18 to 75 years of age (inclusive).
- ✓ 3. Weight range between 40 to 120 kilograms (kg).
- ✓ 4. Confirmed diagnosis of definite or probable MMN.
- ✓ 5. Evidence of:
- ✓ 1. Responsiveness to Ig treatment; and
- ✓ 2. Receiving a stable Ig regimen
- ✓ 6. Documented vaccinations against encapsulated bacteria in accordance with local requirements and vaccine availability.
You may not qualify if…
- ✕ 1. History or presence of significant medical/surgical condition including any acute illness or major surgery considered to be clinically significant or that could impact efficacy assessments.
- ✕ 2. Any coexisting conditions which may interfere with outcome assessments (eg, severe diabetic neuropathy).
- ✕ 3. Concurrent or previous use of rituximab, cyclophosphamide, mycophenolate mofetil, azathioprine, or cyclosporine. If a participant has previously used these medications, the last dose must be at least 6 months prior to randomization.
- ✕ 4. Currently or previously on complement inhibitors including in a clinical trial setting.
- ✕ 5. Prior history (at any time) of N. meningitidis infection.
- ✕ 6. Diagnosis of an autoimmune disorder other than MMN.
- ✕ 7. Positive test results for active human immunodeficiency virus (HIV-1 or HIV-2), hepatitis B surface antigen (HBsAg), or hepatitis C virus (HCV) antibodies during Screening.
- ✕ 8. History of active malignancy within 5 years prior to Screening, except basal cell carcinoma of the skin, curatively resected squamous cell carcinoma of the skin, cervical carcinoma in situ curatively treated or low-grade prostate adenocarcinoma for which appropriate management is observation alone.
Where it's recruiting
Source: ClinicalTrials.gov · NCT06537999 · last updated 2026-06-23